Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO.

Fiche publication

Date publication

avril 2026

Journal

JTO clinical and research reports

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie , Pr MASCAUX Céline

Tous les auteurs :
Falchero L, Amrane K, Godbert B, Leterre B, Madelaine J, Fournel P, Mascaux C, Raimbourg J, Schneider S, Swalduz A, Veillon R, Langlais A, Missy P, Morin F, Westeel V, Girard N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42005788

Résumé

Extensive-stage SCLC (ES-SCLC) is a highly aggressive type of lung cancer with a high risk of early progression and limited survival. Standard of care for first-line treatment is platinum-etoposide chemotherapy plus anti-PD-L1 immune checkpoint inhibitors.